PFIZER has cut the price of Enbrel by 30% to match its rival 'biosimilar' drug from Biogen in Ireland.
Enbrel lost patent protection in Europe earlier this year.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Oct 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Oct 16